Treatment Information

Back

Breast Cancer treatment details. Biologic therapy.

Hematology and Oncology Specialists, New Orleans, LA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:New Orleans, LA
Treatments:Biologic therapyHospital:Hematology and Oncology Specialists
Drugs:Journal:Link
Date:Feb 2015

Description:

Patients:
This phase 2 study involved 34 human epidermal growth factor receptor 2epositive (HER2+) metastatic breast cancer patients who had received prior treatment with trastuzumab. The median patient age was 55 years and all were female.

Treatment:
Patients received biologic therapy with ridaforolimus, an mTOR inhibitor, and trastuzumab, an antibody that inhibits the HER2 receptor.

Toxicities:
There was one treatment-related death due to bowel perforation. Grade 3-4 stomatitis (inflammation of mouth and lips), leucopenia, and neutropenia were also reported.

Results:
The median overall survival was 5.4 months.

Support:
This study was supported by ARIAD Pharmaceuticals, Inc.

Correspondence: Dr. Milton Seiler; email: [email protected]



Back